CompletedNot Applicable

Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions

United States137 participantsStarted 2020-07-07

Plain-language summary

The purpose of this study is to evaluate the Dermal Cooling System for lightening of benign pigmented lesions and to assess additional cosmetic benefits.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female subjects \> 18 years of age.
✓. Subject has one or more benign pigmented lesions (e.g., solar lentigines, freckles, seborrheic keratosis), in an area suitable for treatment.
✓. Subject is willing to have up to 40 treatment sites treated per treatment session depending on the size and nature of the lesions identified.
✓. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
✓. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested.
✓. Subject has read and signed a written informed consent form.
✓. Subject is willing to comply with adjuvant topical regimen, as applicable. -

Exclusion criteria

✕. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery)
✕. Use of products containing glycolic acids, retinol, salicylic acid within the previous 2 weeks
✕. Use of Accutane within the previous 6 months
✕. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
✕. Scars or tattoos in the location of the treatment sites
✕. History of melasma, vitiligo, eczema, or psoriasis in the area of treatment
✕. History of melanoma
✕. Subject is pregnant or intending to become pregnant during the study period

What they're measuring

Improvement in the appearance of the treated areas as assessed by Investigator assessment.

Timeframe: 2-Month Follow-up visit

Safety of the treatment

Timeframe: Up to 12 months

Trial details

NCT IDNCT04493021

SponsorR2 Dermatology

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-05-31

View on ClinicalTrials.gov More Pigmentation trials